Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18332829 | 0.79 | PDPK1 (0.34) | KDM5BALDH1A1ADORA2BADORA2A | |
| SCHEMBL9967679 | 0.73 | — | — | |
| SCHEMBL4546365 | 0.69 | — | — | |
| SCHEMBL22334160 | 0.67 | — | — | |
| SCHEMBL20008191 | 0.67 | — | — | |
| SCHEMBL8199925 | 0.67 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL12549201 | 0.65 | CYP2C19 (0.47) | ALDH1A1 | |
| SCHEMBL21376427 | 0.64 | PDPK1 (0.38) | KDM5BALDH1A1NR1H2 | |
| SCHEMBL18332825 | 0.64 | CCR8 (0.37) | ALDH1A1ADORA2A | |
| SCHEMBL10052275 | 0.64 | HRH2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312175-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2018-04-25 | — | — | EP | disclosed |
| US-RE46375-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-RE46365-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| US-8536192-B2 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO. LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20120135978-A1 | 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE | SHIONOGI & CO., LTD. | 2012-05-31 | — | — | US | disclosed |
| US-8084460-B2 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090203723-A1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135978-A1 | 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE | HRH2, GPR27, HRH4 | KDM5B 2593/4885ALDH1A1 937/4885ADORA2B 928/4885 |
| US-20090203723-A1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | HRH2, GPR27, HRH4 | KDM5B 2593/4885ALDH1A1 937/4885ADORA2B 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.